Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piemonte association in type 2 diabetes mellitus
NCT05028140Phase 3Recruiting
- Sponsor
- EMS
- Start
- Oct 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin + pioglitazone in type 2 diabetes mellitus (T2DM), sponsored by EMS. Started Oct 2024; status: recruiting.
02
Drugs
empagliflozin + pioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05028140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05028140.